CytoMed Therapeutics Unveils Financial Results and Progress Updates
CytoMed Therapeutics Reports Financial Results
CytoMed Therapeutics Limited (NASDAQ: GDTC) is excited to share its financial results for the six months ended June 30, 2024, along with important clinical and corporate developments. The company remains dedicated to pioneering allogeneic cell-based immunotherapies designed to fight various cancers, including both blood and solid tumors.
Commitment to Cancer Care
"Our commitment revolves around developing accessible, off-the-shelf therapies aimed at addressing the needs of cancer patients who have limited options," stated Peter Choo, the Chairman of CytoMed. He emphasized that their growth strategy leverages Southeast Asia's cost-effective infrastructure, which, in conjunction with collaborations, will enhance international operations.
Clinical Updates: The ANGELICA Trial
The company obtained approval from the Health Sciences Authority in Singapore to conduct the ANGELICA Trial, a first-in-human Phase I clinical trial. This initiative aims to utilize healthy donor blood to produce CAR-?? T cells, also known as CTM-N2D. The trial, which is being conducted in collaboration with the National University Hospital, involves recruiting healthy blood donors and advanced cancer patients for further studies.
Innovative Technologies and Research Progress
As of September 2024, CytoMed is advancing two licensed technologies: donor blood cell-based CAR-?? T cell technology and induced pluripotent stem cell-derived ?? NKT cell technology, with patents already issued in multiple countries. These technologies showcase the company's commitment to advancing the frontiers of cancer treatment.
Financial Overview
For the six months ended June 30, 2024, CytoMed's unaudited net loss stood at S$1.09 million (approximately US$803,235). Excluding public listing costs, this figure adjusts to S$934,623 (around US$689,657). As of mid-2024, the company reported cash and bank balances totaling S$6.47 million (about US$4.78 million), enabling them to pursue research and operational goals.
Research and Development Spending
Research and development costs reached S$974,402 (US$719,010) during the same period, marking a rise from S$811,319 in the previous year due to increased pre-clinical activities and employee benefits. However, efficiencies were achieved with lower costs in some operational areas.
General and Administrative Expenses
General and administrative expenses fell to S$902,910 (approximately US$666,256) from S$1.50 million the previous year, mainly due to non-recurring expenses following the IPO. This strategic change allows for better financial management while maintaining growth momentum.
Upcoming Conference and Investor Meetings
Exciting news for the investment community! CytoMed has scheduled a conference call on October 8, 2024, at 9 a.m. ET (9 p.m. SGT), where management will provide further insights into the company's direction and updates. Investors interested in one-on-one meetings may do so from October 28 to November 1, 2024, in New York City. For scheduling, please reach out to the company.
About CytoMed Therapeutics Limited
Founded in 2018 after a spin-off from the Agency for Science, Technology and Research (A*STAR) in Singapore, CytoMed is at the forefront of developing novel immunotherapies aimed at treating various cancers. Their innovative approach strives to overcome the limitations of existing therapies while taking inspiration from successful CAR-T treatments in hematological malignancies.
Frequently Asked Questions
What are the main focuses of CytoMed Therapeutics?
CytoMed Therapeutics specializes in developing unique cell-based immunotherapies designed to treat a wide range of cancers.
How has CytoMed performed financially over the last six months?
The company reported a net loss of S$1.09 million, but they have significant cash reserves to fund ongoing research and development efforts.
What is the ANGELICA Trial?
The ANGELICA Trial is CytoMed's first-in-human Phase I clinical trial using healthy donor blood to manufacture CAR-?? T cells for cancer treatment.
When is the upcoming conference call scheduled?
The conference call is set for October 8, 2024, at 9 a.m. ET.
How can I contact CytoMed for investor meetings?
Investors can reach out via email at enquiry@cytomed.sg to schedule meetings during their New York City visit.
About Investors Hangout
Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/
Disclaimer: The content of this article is solely for general informational purposes only; it does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice; the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. The author's interpretation of publicly available data shapes the opinions presented here; as a result, they should not be taken as advice to purchase, sell, or hold any securities mentioned or any other investments. The author does not guarantee the accuracy, completeness, or timeliness of any material, providing it "as is." Information and market conditions may change; past performance is not indicative of future outcomes. If any of the material offered here is inaccurate, please contact us for corrections.
Related Articles
- SLR Investment Corp. Expands Portfolio with New Acquisition
- ISS A/S Updates on Share Buyback Program Progress
- Popular, Inc. Prepares for Third Quarter Financial Results
- Understanding IT Leaders' Growing Concerns Over Cloud Costs
- Valoe Corporation Expands Convertible Bond Subscription Period
- InspireSemi Announces Key Business Update and CFO Change
- Aspen Neuroscience CFO Kameel Farag to Present Key Updates
- Innovative Hair Loss Treatment Shows Promising Results
- Frank's RedHot Unveils $20,000 Tailgate Scholarship for Fans
- Globo S.A. Unveils Cash Tender Offers for 2030 and 2032 Notes
Recent Articles
- McDermott Secures Major LNG Project Contract for Growth
- Antelope Enterprise Reports 2024 Financial Results with New Ventures
- HungryPanda Secures $55 Million to Expand Global Reach
- Leap Therapeutics Completes Enrollment in DKN-01 Study for Cancer
- Empowering Cybersecurity: Strong Passwords for All
- TapestryHealth Welcomes New Faces to Board of Directors
- NetSPI Celebrated as Top Workplace for 2024 by Oregonian
- NRx Pharmaceuticals Achieves Stability Milestone for NRX-100
- Gogo's Acquisition of Satcom Direct: A Game-Changer in Aviation
- Empowering Women in HVACR: Highlights from Annual Convention
- British Vlogger Highlights Dunhuang's Cultural Greatness
- EchoStar Corporation's Exchange Offers for DBS Notes Explained
- Transforming Life Sciences: Magnolia and Veeva's New Integration
- Domino's Offers Half Price Pizza for National Pizza Month
- Eller Group Welcomes Ross Ramsey: A New Dimension in Strategy
- Businesses Face Rising Threats from Deepfake Scams in 2024
- Impressive Growth of the MICE Industry: Key Insights and Trends
- Global Wire-Rope Market Poised for Rapid Growth by 2032
- Future Growth of Electric Trolling Motors Estimated at 3.6% CAGR
- Navient's New Strategy Sparks Hope Amid Legacy Loan Challenges
- Zeta Global Holdings: Increasing Growth and Market Confidence
- Exploring the Future of Behavioral Rehabilitation Market Growth
- Jack in the Box Expands Reach with 12 New Locations in Chicago
- Growth Projections for Bariatric Surgery Devices Through 2033
- Tide Capital Anticipates Crypto Surge After Fed Rate Cuts
- Equity Funds Experience Record Inflows Amid Market Changes
- PCE Data Sparks Interest in Potential Fed Rate Cuts Soon
- Talus Network's Nexus Revolutionizes Autonomous AI on Blockchain
- WPP Energy Revolutionizes Energy Sector with Innovations
- Prime Medicine Collaborates with Bristol Myers Squibb for Innovative T-Cell Therapies
- Tonix Pharmaceuticals Shares Insights on Long COVID Workshop
- Mercury Systems Boosts KC-46A Tanker Fleet with Enhanced Tech
- CytoMed Therapeutics Updates on Clinical Progress and Finances
- BioStem Technologies Seeks Nasdaq Uplisting with Form 10 Registration
- Exploring Nurix Therapeutics' Innovations at a Leading Conference
- Sable Resources Expands Copper Queen Project with New Discoveries
- Exploring Investment Opportunities in Consumer Discretionary ETFs
- Captivision Inc. Sees 22% Revenue Growth in Recent Results
- Market Reflections: Powell's Insights and Global Trends
- Akero Therapeutics to Showcase Innovations at Upcoming Virtual Conference
- Exploring Growth Stocks: Broadcom and AMD Amid Market Bounce
- Perspective Therapeutics Shares Insights at European Congress
- BioCryst Pharmaceuticals Secures $69 Million Influenza Contract
- Gain Therapeutics Shares Promising Phase 1 Data on GT-02287
- Hydreight Technologies Unveils Share Buyback Initiative
- Vor Bio Welcomes Dr. Han Choi as Chief Financial Officer
- Key Leadership Appointment at Silvaco Enhances Legal Expertise
- Onity Group's Strategic Moves to Restructure Capital for Growth
- West Red Lake Gold Emphasizes Commitment to Reconciliation
- Alamos Gold Announces Upcoming Conference for Q3 2024 Results